Tarsus is a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients with unmet needs. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, was evaluated in two pivotal trials collectively involving more than 800 patients for Demodex blepharitis. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment-related adverse events. Both trials also demonstrated that TP-03 was generally safe and well-tolerated. TP-03 is now also being studied for the treatment of MGD in patients with Demodex mites.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Dec 16, 2022
Dec 15, 2022
Nov 09, 2022